These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 2146258

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M, Cavallo LG, Agnelli G, Mele A, Bürgi R, Heim J, Semeraro N.
    Thromb Haemost; 1993 May 03; 69(5):466-72. PubMed ID: 8391727
    [Abstract] [Full Text] [Related]

  • 5. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
    Holvoet P, Laroche Y, Lijnen HR, Van Hoef B, Brouwers E, De Cock F, Lauwereys M, Gansemans Y, Collen D.
    Eur J Biochem; 1992 Dec 15; 210(3):945-52. PubMed ID: 1483477
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
    Nelles L, Lijnen HR, Collen D, Holmes WE.
    J Biol Chem; 1987 Apr 25; 262(12):5682-9. PubMed ID: 3106341
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V, Pannell R, Broeze RJ, Mao J.
    J Clin Invest; 1988 Dec 25; 82(6):1956-62. PubMed ID: 2974047
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
    Li XK, Lijnen HR, Nelles L, Hu MH, Collen D.
    Biochim Biophys Acta; 1992 Sep 04; 1159(1):37-43. PubMed ID: 1390910
    [Abstract] [Full Text] [Related]

  • 16. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Vandamme AM, Dewerchin M, Lijnen HR, Bernar H, Bulens F, Nelles L, Collen D.
    Eur J Biochem; 1992 Apr 01; 205(1):139-46. PubMed ID: 1313361
    [Abstract] [Full Text] [Related]

  • 17. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
    Lijnen HR, Van Hoef B, Nelles L, Collen D.
    J Biol Chem; 1990 Mar 25; 265(9):5232-6. PubMed ID: 1969415
    [Abstract] [Full Text] [Related]

  • 18. Design and evaluation of a thrombin-activable plasminogen activator.
    Yang WP, Goldstein J, Procyk R, Matsueda GR, Shaw SY.
    Biochemistry; 1994 Mar 01; 33(8):p606-12. PubMed ID: 8117652
    [Abstract] [Full Text] [Related]

  • 19. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.
    Gurewich V, Pannell R.
    Blood; 1987 Mar 01; 69(3):769-72. PubMed ID: 2949785
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.